25 Sept 2015. PhotoSonix Medical announced today that it has closed on an initial seed round of funding led by a blue chip group of sophisticated angels and medtech executives. The Company has now raised over $700,000 to fund development of its innovative and proprietary CLENS technology. Mark Schafer, PhD, President and COO, commented, “We are fortunate to have the support of a true value added group of investors. They bring a wealth of experience and access to an extensive network of contacts and resources.” Dr. Schafer added, “We are looking forward to providing a truly effective drug-free solution to acne sufferers. We believe CLENS has the potential to establish a new standard of care to this large and highly under-served market.” Given strong interest in the Seed round, the Company may expand the size of the financing.